Apellis Pharmaceuticals (NASDAQ: APLS) rocketed 136% in premarket trading on Tuesday, March 31, 2026, after Biogen (BIIB) announced a definitive agreement to acquire the company for $41 per share in cash — approximately $5.6 billion upfront. The deal represents a 140% premium to